What does schizophrenia teach us about antipsychotics?

Gary Remington, Ofer Agid, George Foussias, Gagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, Margaret Hahn

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.

RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.

CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.

OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.

Original languageEnglish
Pages (from-to)S14-S18
JournalCanadian journal of psychiatry. Revue canadienne de psychiatrie
Volume60
Issue number3
Publication statusPublished - 2015 Mar 1
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Clozapine
Psychotic Disorders
Polypharmacy
Neurobehavioral Manifestations
Magic
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Remington, G., Agid, O., Foussias, G., Fervaha, G., Takeuchi, H., Lee, J., & Hahn, M. (2015). What does schizophrenia teach us about antipsychotics? Canadian journal of psychiatry. Revue canadienne de psychiatrie, 60(3), S14-S18.

What does schizophrenia teach us about antipsychotics? / Remington, Gary; Agid, Ofer; Foussias, George; Fervaha, Gagan; Takeuchi, Hiroyoshi; Lee, Jimmy; Hahn, Margaret.

In: Canadian journal of psychiatry. Revue canadienne de psychiatrie, Vol. 60, No. 3, 01.03.2015, p. S14-S18.

Research output: Contribution to journalReview article

Remington, G, Agid, O, Foussias, G, Fervaha, G, Takeuchi, H, Lee, J & Hahn, M 2015, 'What does schizophrenia teach us about antipsychotics?', Canadian journal of psychiatry. Revue canadienne de psychiatrie, vol. 60, no. 3, pp. S14-S18.
Remington, Gary ; Agid, Ofer ; Foussias, George ; Fervaha, Gagan ; Takeuchi, Hiroyoshi ; Lee, Jimmy ; Hahn, Margaret. / What does schizophrenia teach us about antipsychotics?. In: Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2015 ; Vol. 60, No. 3. pp. S14-S18.
@article{22b71878e38e4136bc74bbb3cabe215b,
title = "What does schizophrenia teach us about antipsychotics?",
abstract = "METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.",
author = "Gary Remington and Ofer Agid and George Foussias and Gagan Fervaha and Hiroyoshi Takeuchi and Jimmy Lee and Margaret Hahn",
year = "2015",
month = "3",
day = "1",
language = "English",
volume = "60",
pages = "S14--S18",
journal = "Canadian Journal of Psychiatry",
issn = "0706-7437",
publisher = "Canadian Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - What does schizophrenia teach us about antipsychotics?

AU - Remington, Gary

AU - Agid, Ofer

AU - Foussias, George

AU - Fervaha, Gagan

AU - Takeuchi, Hiroyoshi

AU - Lee, Jimmy

AU - Hahn, Margaret

PY - 2015/3/1

Y1 - 2015/3/1

N2 - METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.

AB - METHOD: Three specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.RESULTS: Evidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.CONCLUSIONS: Advances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.OBJECTIVE: To examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.

UR - http://www.scopus.com/inward/record.url?scp=85018719316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018719316&partnerID=8YFLogxK

M3 - Review article

C2 - 25886675

AN - SCOPUS:85018719316

VL - 60

SP - S14-S18

JO - Canadian Journal of Psychiatry

JF - Canadian Journal of Psychiatry

SN - 0706-7437

IS - 3

ER -